Minor Cannabinoid Use Among Medical Cannabis Patients.

As cannabis legalization spreads across the United States, new types of cannabinoids beyond the well-known THC and CBD are becoming increasingly available to patients. This research surveyed over 1,700 medical cannabis patients to understand who is using these emerging cannabinoids—such as delta-8 THC, CBG, CBN, and THC-O—and why. The study found that patients are actively using a diverse range of these newer products, with many using them daily. The most popular cannabinoids were CBD, regular delta-9 THC, delta-8 THC, and THCA, consumed primarily through smoking flower, vape pens, and edibles.

Beyond just documenting usage patterns, the research revealed important motivations behind these choices. Most patients reported using cannabis to manage medical conditions and improve their overall well-being, and notably, the majority said they had reduced or stopped taking conventional pharmaceuticals because of their medical cannabis use. This finding suggests that patients may be self-treating conditions and potentially replacing traditional medications with cannabis products, a practice with significant health implications.

The study's main takeaway is a call to action: as these emerging cannabinoids become more widely available and used, there's an urgent need for better public education and health information. Patients are experimenting with novel cannabinoids without clear guidance about their effects, safety, or how they compare to established options. This research highlights a gap between product availability and scientific understanding—we need more research on these emerging cannabinoids and better communication to help patients make informed decisions about their medical use.